‹ Screener

DR REDDYS LABORATORIES LTD

RDY · Pharmaceutical Preparations · EDGAR filings ↗

Grade

B83

Scaled, high-return global generics pharma with top-decile margins and returns but flat earnings growth.

Strengths

Risks

Notable findings

Key metrics

Gross margin
58.5%
Operating margin
22.1%
Net margin
17.6%
Return on equity
17.0%
Return on assets
11.6%
ROIC
16.4%
Revenue growth (QoQ)
13.8%
Net-income growth
0.4%
Debt / equity
0.0×
Interest coverage
25.4×
Current ratio
1.9×
Free cash flow
$223M
Tangible book value
$3.8B
Cash & investments
$172M

Supply chain

Customers (0)

    Suppliers (3)

    • Alvotech
    • Nestlé Health Science India
    • Shanghai Henlius Biotech, Inc.

    Named in the 10-K; linked when we track them.

    Recent filings

    FormFiledPeriodAccession
    20-F2026-05-292026-03-310001575872-26-000381 ↗
    20-F2025-06-062025-03-310001575872-25-000393 ↗
    20-F2024-06-122024-03-310001575872-24-000660 ↗
    20-F2023-06-132023-03-310001575872-23-000951 ↗
    20-F2022-06-272022-03-310001575872-22-000576 ↗
    20-F2021-06-302021-03-310001575872-21-000138 ↗
    20-F2020-06-152020-03-310001575872-20-000145 ↗
    20-F2019-06-032019-03-310001575872-19-000144 ↗
    20-F2018-06-152018-03-310001575872-18-000109 ↗
    20-F2017-06-192017-03-310001193125-17-207210 ↗
    20-F2016-06-232016-03-310001193125-16-630015 ↗